ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK)

HKD 5.05

(0.0%)

Net Income Summary of ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s latest annual net income in 2023 was -379.45 Million CNY , up 5.82% from previous year.
  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s latest quarterly net income in 2024 Q2 was -89.05 Million HKD , up 0.15% from previous quarter.
  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc. reported an annual net income of -402.89 Million CNY in 2022, up 45.03% from previous year.
  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc. reported an annual net income of -732.94 Million CNY in 2021, down 0.0% from previous year.
  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc. reported a quarterly net income of -89.05 Million HKD for 2024 Q2, up 0.15% from previous quarter.
  • ImmuneOnco Biopharmaceuticals (Shanghai) Inc. reported a quarterly net income of -225.38 Million HKD for 2023 Q4, down -101.45% from previous quarter.

Annual Net Income Chart of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (2023 - 2021)

Historical Annual Net Income of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (2023 - 2021)

Year Net Income Net Income Growth
2023 -379.45 Million CNY 5.82%
2022 -402.89 Million CNY 45.03%
2021 -732.94 Million CNY 0.0%

Peer Net Income Comparison of ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Name Net Income Net Income Difference
Uni-Bio Science Group Limited 70.87 Million HKD 635.384%
CK Life Sciences Int'l., (Holdings) Inc. 17.25 Million HKD 2299.762%